Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Targeting CD19 May Yield Paradigm-Altering Technology

May 9th 2014

For the past two decades, researchers have been exploring B-cell specific antigens in hopes of developing a new anticancer target that would mirror the success of the CD20-targeting rituximab (Rituxan). Now, strategies aimed at CD19 are proving particularly promising.

Dr. Younes Discusses the Future of Treating Lymphoid Malignancies

May 6th 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of treating lymphoid malignancies.

FDA Approves Home Administration for Omacetaxine Mepesuccinate

May 5th 2014

The FDA has approved subcutaneous omacetaxine mepesuccinate injection for home administration in patients with chronic or accelerated phase CML who are resistant or intolerant to treatment with TKIs.

Dr. Goy on NCCN Guidelines for Lymphomas

May 2nd 2014

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses NCCN guidelines for the treatment of lymphomas.

Emerging Treatments and Trends in Hematologic Malignancies: A Q&A With Anas Younes, MD

April 30th 2014

At the 18th Annual International Congress on Hematologic Malignancies, Anas Younes, MD, sat down with Oncology & Biotech News to discuss trends in the management of hematologic malignances.

Dr. Seymour Discusses the Results of the PRIMA Study

April 28th 2014

John F. Seymour, MBBS, FRACP, PhD, from the Department of Hematology at the Peter MacCallum Cancer Centre in East Melbourne, Australia, discusses the results of the PRIMA study, which evaluated the benefit of maintenance therapy with rituximab after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy in patients with advanced follicular lymphoma.

Dr. Brentjens on the Potential Application of CAR-Modified T Cell Technology

April 24th 2014

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the potential application of CAR-modified T cell technology.

FDA Approves Siltuximab for Multicentric Castleman's Disease

April 23rd 2014

The FDA has approved the anti-IL-6 chimeric monoclonal antibody siltuximab as a treatment for HIV- and HHV-8-negative patients with multicentric Castleman's disease.

Dr. Komrokji on Pacritinib for the Treatment of Myelofibrosis

April 21st 2014

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses an analysis of pacritinib for the treatment of myelofibrosis.

FDA Approves First-Line Ofatumumab for Fludarabine-Ineligible Patients With CLL

April 17th 2014

The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.

Dr. Wierda on Treating CLL Patients with 17p Deletion

April 16th 2014

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with CLL who harbor the 17p deletion.

Treatment Landscape for Mantle Cell Lymphoma Continues to Evolve

April 16th 2014

Lymphoma expert Andre Goy, MD, provides insight into the rapidly changing treatment landscape for patients with mantle cell lymphoma.

Dr. Faderl on Chemotherapy and FLT3 Inhibitors in AML

April 11th 2014

Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, discusses combining and sequencing chemotherapy and FLT3 inhibitors for the treatment of patients with acute myeloid leukemia (AML).

Dr. Melnick on Targeting EZH2 in DLBCL

April 10th 2014

Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B-cell lymphoma.

Hitting the Target: How Druker's Persistence Helped Launch a New Mode of Attack

April 10th 2014

Take a prognosis of three years, multiply it by 10, and what do you get? A staggering improvement in the survival of patients with chronic myeloid leukemia (CML), and a crucial steppingstone on the road to the targeted treatment of cancer.

Dr. Donato on Advances in the Prevention of GVHD

April 9th 2014

Michele L. Donato, MD, medical director, Blood and Marrow Collection Facility, John Theurer Cancer Center, discusses advances in the prevention of graft-versus-host disease (GVHD).

Dr. Schenkein on AG-221 for the Treatment of AML

April 8th 2014

David Schenkein, MD, Chief Executive Officer, Agios Pharmaceuticals, discusses AG-221 for the treatment of acute myeloid leukemia (AML).

Dr. Younes on the Implications of Ibrutinib's Approval for MCL

April 4th 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the implications of ibrutinib's approval for patients with mantle cell lymphoma (MCL).

Targeted Therapies Usher in a New Era in CLL: Wierda Discusses Key Facets of Emerging Agents

April 4th 2014

The approval of the first small-molecule, targeted therapy for patients with chronic lymphocytic leukemia (CLL) launches a new era that promises to transform management of the disease, yet significant challenges in translating research advances into improvements in long-term outcomes remain

Dr. Erba on FLT3 Inhibitors for the Treatment of AML

April 2nd 2014

Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses the excitement around FLT3 inhibitors for the treatment of acute myeloid leukemia (AML).